金吾财讯 | 据路透，默克集团(Merck KGaA)表示，正就收购SpringWorks Therapeutics(SWTX)进行后期谈判，交易金额约为35亿美元。这笔交易可能使其获得最近获批的罕见病药物，并扩大其实验性癌症治疗产品组合。默克在一份声明中表示，双方尚未做出最终决定，也未达成任何具有法律约束力的协议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.